Inhibition of Platelet Production Induced by an Antiplatelet Drug, Anagrelide, in Normal Volunteers

• DOI: 10.1055/s-0038-1661206
• Publication Date: 2018-07-19T22:31:25Z
• Authors: W Abe Andes; Robert J Noveck; J S Fleming
• Keywords: Anagrelide; Thrombocytosis; Antiplatelet drug; Polycythemia rubra vera; Plateletpheresis

Summary Administration of anagrelide, an antiplatelet agent, to ten normal male subjects was accompanied by asymptomatic fall in platelet count. The drop gradual and usually occurred within two weeks. Only a slight shortening survival seen. Bone marrow morphology appeared normal. Measurement production rates showed reduced response thrombocytopenia. A substantial increase the percentage large platelets observed drug treated subjects. These observations are compatible with selective inhibition production. Based upon these findings, use anagrelide will probably be best limited short-term applications or conditions where lowering count may desired such as polycythemia rubra vera idiopathic thrombocytosis.